Review

streptococcus pneumoniae atcc 49619 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC streptococcus pneumoniae atcc 49619
Streptococcus Pneumoniae Atcc 49619, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 203 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/streptococcus+pneumoniae+atcc+49619/Streptococcus+pneumoniae/pmc13148051-0-0-2
Average 94 stars, based on 203 article reviews

streptococcus pneumoniae atcc 49619 - by Bioz Stars, 2026-09

94/100 stars

Images

Control:

Article Title: Trimethoprim-sulfamethoxazole susceptibility in beta-hemolytic streptococci in a Canadian tertiary center.
Article Snippet: Each isolate, initially identified by latex agglutination (MedicoDxTM Strep-Select Grouping Kit (MedicoDx, Ottawa, Canada)) and/or MALDITOF (Matrix-Assisted Laser Desorption/Ionization - Time of Flight) mass spectrometry (VITEK® MS, IVD Knowledge Base v3.2, bioMérieux, Marcy-l’Étoile, France), was subcultured from the primary clinical specimen medium on tryptic soy agar with 5% sheep blood (TSA, Oxoid, Basingstoke, UK) and incubated for 18–24 hours at ~35◦C in 5% CO2. .. Quality control was performed according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) [18] and Clinical and Laboratory Standards Institute (CLSI) [19] recommendations using Streptococcus pneumoniae ATCC 49619. ..

Article Title: Assessment of bacterial profile of drinking water from different sources in Nekemte and their antibiotic susceptibility pattern, Western Ethiopia.
Article Snippet: .. Repeatability was guaranteed by the inclusion of quality control strains like Escherichia coli ATCC 25922 and Streptococcus pneumoniae ATCC 49619. ..

Bacteria:

Article Title: Clinical significance and simultaneous microevolution of two closely-related nontuberculous mycobacteria species
Article Snippet: .. No acid-fast bacilli were detected in smears, and no bacteria grew from cultures on blood agar at 35 °C for 48 h although the positive control, Streptococcus pneumoniae ATCC 49619, grew. .. He was empirically administered oral azithromycin (0.5 g, qd) for 3 days, after which fever, cough, sore throat, muscle soreness, and dizziness resolved, but mild cough with scant sputum persisted.

Positive Control:

other:

Article Title: Cationic Liposome-Fused Endolysin Lys40 Overcomes Outer Membrane Barriers and Enhances Survival in Salmonella -Infected Chicks
Article Snippet: Streptococcus pneumoniae ATCC 49619 , 1.

Article Title: Benzoxaborole-modified azithromycins inhibit translation without inducing ermC expression
Article Snippet: Streptococcus pneumoniae ATCC 49619 , 0.06 , 0.5 , 0.125 , 0.125 , 0.125.

Image Search Results

Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Effects of azeliragon on the in vitro growth of S. pneumoniae . Dose–response relationships of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) following treatment with increasing concentrations of azeliragon. Bacterial growth was measured after 18 h of incubation and expressed as OD 600 . Effects of azeliragon on the growth kinetics of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Bacteria were cultured under control conditions or with different concentrations of azeliragon, and OD 600 was recorded at indicated time points to generate growth curves. Data were presented as mean ± SD. The experiments were performed with three independent biological replicates ( n = 3). “ns” represented no significant difference, ** p < 0.01.

Article Snippet: To further assess the effects of azeliragon on pneumococcal growth, the reference strain S. pneumoniae ATCC 49619 and two clinical isolates (1057 and 1044) were examined under different drug concentrations.

Techniques: In Vitro, Incubation, Bacteria, Cell Culture, Control

Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: Time-kill activity and biofilm disruption effects of azeliragon against S. pneumoniae . Time-kill curves of S. pneumoniae ATCC 49619 (A) , S. pneumoniae 1057 (B) , and S. pneumoniae 1044 (C) treated with azeliragon (4× MIC). Bacteria were cultured under control conditions or treated with azeliragon (4× MIC) or vancomycin (4× MIC), and viable counts (CFU/mL) were determined at indicated time points. Effects of azeliragon (4× MIC) on biofilm biomass of S. pneumoniae ATCC 49619 (D) , S. pneumoniae 1057 (E) , and S. pneumoniae 1044 (F) . Mature biofilms were treated with the indicated drugs for 24 h and quantified by crystal violet staining. Results are expressed as OD₅₇₀. Data were presented as mean ± SD. Data were presented as mean ± SD. The experiments were performed with six independent biological replicates ( n = 6). Group comparisons for biofilm assays were analyzed by one-way ANOVA followed by Tukey’s multiple-comparison test. “ns” represented no significant difference, *** p < 0.001.

Techniques: Activity Assay, Disruption, Bacteria, Cell Culture, Control, Staining, Comparison

In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

Journal: Frontiers in Medicine

Article Title: Protective effects of the RAGE inhibitor azeliragon as a potential anti- Streptococcus pneumoniae therapeutic in sepsis models

doi: 10.3389/fmed.2026.1793580

Figure Lengend Snippet: In vivo protective effects of azeliragon in a mouse infection model. (A) Determination of the infectious dose of S. pneumoniae 1044. (B) Therapeutic efficacy of azeliragon in the pneumonia model. (C) Seven-day survival curves of mice with sepsis induced by S. pneumoniae ATCC 49619. Mice received vehicle control, bacterial control, azeliragon (5 mg/kg or 10 mg/kg), or vancomycin (10 mg/kg). Each group contained 10 mice. Survival was monitored continuously. (D) Seven-day survival curves of mice with sepsis induced by the clinical S. pneumoniae isolate 1044. Experimental groups and treatments were identical to those in (A) . Survival data were plotted using the Kaplan–Meier method, and statistical significance was determined using the log-rank (Mantel–Cox) test. “ns” represented no significant difference, * p < 0.05, ** p < 0.01, and *** p < 0.001.

Techniques: In Vivo, Infection, Drug discovery, Control

Review

streptococcus pneumoniae atcc 49619 (ATCC)

Structured Review

Images

Related Articles

Control:

Bacteria:

Positive Control:

other:

Similar Products

Image Search Results